• Novartis AG, of Basel, Switzerland, and Baylor Research Institute, the research arm of Baylor Health Care System, signed a deal for Novartis to exclusively license Baylor's patents pertaining to the treatment of systemic onset juvenile idiopathic arthritis using interleukin-1 beta agonists.
